Rate My Professor Peter Chapman

Dr. Peter Chapman is a rheumatologist and researcher affiliated with the Department of Medicine at the University of Otago, Christchurch, within the Faculty of Medicine, and serves as Clinical Director of the Department of Rheumatology, Immunology and Allergy at Christchurch Hospital. He earned his MBChB and MD from the University of Otago, is a Fellow of the Royal Australasian College of Physicians (FRACP), and holds a Postgraduate Diploma in Musculoskeletal Medicine (PGDipMSM). His career encompasses clinical practice in rheumatology, academic contributions through the University of Otago, and a sabbatical at the Mayo Clinic in Rochester, Minnesota. Chapman has contributed to musculoskeletal medicine education, including involvement in courses like MSME701 Clinical Diagnosis at the University of Otago.

Chapman's research centers on gout and systemic sclerosis, addressing clinical challenges such as urate-lowering therapies, flare prediction, and disease progression. Key publications include 'Colchicine concentrations and relationship with colchicine intolerance: post-hoc analysis of a randomised clinical trial of colchicine for gout flares during allopurinol initiation' (Annals of the Rheumatic Diseases, 2025, with Daniel Wright, Chris Frampton, Nicola Dalbeth); 'Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Strategy: A Post Hoc Analysis of a Randomized Clinical Trial' (Arthritis Care & Research, 2024, with Christopher Frampton, Nicola Dalbeth); 'Gout in renal transplant recipients' (with Lisa Stamp, Leah Ha, Martin Searle, John O'Donnell, Chris Frampton); 'The challenges of managing gout in primary care: Results of a best-practice audit' (2019, with Lisa K. Stamp, Ben Hudson, Christopher Frampton); 'Lack of effect of tart cherry concentrate dose on serum urate in people with gout' (Rheumatology, 2020, with Lisa K. Stamp, Christopher Frampton); 'Development of Preliminary Remission Criteria for Gout Using Delphi and Conjoint Analysis Techniques' (Arthritis & Rheumatology, 2016, with multiple authors); 'Changes in clinical disease activity are weakly linked to changes in MRI-defined synovitis and bone marrow lesions in a multicentre longitudinal study of early rheumatoid arthritis' (2017, with Peter Chapman, Terina Pollock, Dena D'Souza); 'Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis' (Annals of the Rheumatic Diseases, 2019, with Peter Chapman, John O'Donnell); and 'Allopurinol and kidney function: An update' (Current Opinion in Rheumatology, 2015, with Suetonia C. Palmer). With over 90 research outputs and more than 4,000 citations, his work informs gout management strategies, including dosing in renal impairment and prophylaxis needs. He has co-authored on topics like gout comorbidities, joint replacement rates, and scleroderma phenotypes.